Advertisement

Tumor Biology

, Volume 35, Issue 10, pp 10497–10502 | Cite as

Endothelial cell-specific molecule-1: a potential serum marker for gastric cancer

  • Zhongchuan Lv
  • Yongsheng Fan
  • Hongbing Chen
  • Dawei Zhao
Research Article

Abstract

No ideal serum markers for gastric cancer (GC) screening have been identified. The aim of this study was to determine the usefulness of endothelial cell-specific molecule-1 (ESM-1) as a serum marker for GC. The ESM-1 levels in serum specimens from 114 patients with GC and 55 health subjects were measured using a sandwich ELISA kit. Receiver operating characteristic (ROC) curve was calculated to assess the diagnostic value of ESM-1. Survival curves by the Kaplan-Meier method were plotted to display overall survival distributions. Univariable and multivariable Cox regression analyses were performed to assess independent prognostic factors for overall survival in GC. We showed that the ESM-1 levels in the serum of patients with GC (83.7 ± 16.2 pg/mL) were significantly elevated compared to health subjects (44.7 ± 16.4 pg/mL). The accuracy, sensitivity, and specificity of ESM-1 for GC were 0.946, 98, and 80 %, respectively, by ROC curve analysis. The positive and negative predictive values were 91 and 93.6 %, respectively. The likelihood ratios of a positive or negative test result were 20.9 and 0.14, respectively. When analyzed with a Cox regression model, a higher serum ESM-1 level (≥84.2 pg/mL) was correlated with poor prognosis. This study suggests that serum ESM-1 level is increased in patients with GC and that ESM-1 can be used as a potential serum marker for early detection and prognosis evaluation of GC.

Keywords

Endothelial cell-specific molecule-1 Gastric cancer Serum marker Early detection Prognosis 

Notes

Acknowledgments

No funding was received for the present study. We would like to thank Yifei Zhang for helping collecting the clinical data.

Conflicts of interest

None

Supplementary material

13277_2014_2319_Fig3_ESM.gif (60 kb)
Fig. S1

Serum concentration and receiver operating characteristics (ROC) curve of carcinoembryonic antigen (CEA). (a) Serum CEA levels in normal subjects (N) and in patients with GC. (b) Serum CEA levels in normal individuals (N), patients with early stage GC (stage I/II), and patients with late stage GC (stage III/IV). (c) The ROC curve for CEA in serum collected from patients with GC and health subjects. (GIF 59 kb)

13277_2014_2319_MOESM1_ESM.tif (1.3 mb)
High resolution image (TIFF 1.31 mb)

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Yeh JM, Goldie SJ, Kuntz KM, Ezzati M. Effects of Helicobacter pylori infection and smoking on gastric cancer incidence in China: a population-level analysis of trends and projections. Cancer Causes Control. 2009;20:2021–9.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014;17:26–33.CrossRefPubMedGoogle Scholar
  4. 4.
    Wanebo HJ, Kennedy BJ, Chmiel J, Steele Jr G, Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993;218:583–92.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271:20458–64.CrossRefPubMedGoogle Scholar
  6. 6.
    Bechard D, Meignin V, Scherpereel A, Oudin S, Kervoaze G, Bertheau P, et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res. 2000;37:417–25.CrossRefPubMedGoogle Scholar
  7. 7.
    Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006;1765:25–37.PubMedGoogle Scholar
  8. 8.
    Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T, et al. Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res. 2006;12:4575–82.CrossRefPubMedGoogle Scholar
  9. 9.
    Leroy X, Aubert S, Zini L, Franquet H, Kervoaze G, Villers A, et al. Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. Histopathology. 2010;56:180–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Ji NY, Kim YH, Jang YJ, Kang YH, Lee CI, Kim JW, et al. Identification of endothelial cell-specific molecule-1 as a potential serum marker for colorectal cancer. Cancer Sci. 2010;101:2248–53.CrossRefPubMedGoogle Scholar
  11. 11.
    Liu N, Zhang LH, Du H, Hu Y, Zhang GG, Wang XH, et al. Overexpression of endothelial cell specific molecule-1 (ESM-1) in gastric cancer. Ann Surg Oncol. 2010;17:2628–39.CrossRefPubMedGoogle Scholar
  12. 12.
    Tanigawa N, Amaya H, Matsumura M, Lu C, Iki M. Association between tumor angiogenesis and Borrmann type 4 carcinomas of the stomach. Oncology. 1998;55:461–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr. 2007;96:644–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Akobeng AK. Understanding diagnostic tests 1: sensitivity, specificity and predictive values. Acta Paediatr. 2007;96:338–41.CrossRefPubMedGoogle Scholar
  15. 15.
    Akobeng AK. Understanding diagnostic tests 2: likelihood ratios, pre- and post-test probabilities and their use in clinical practice. Acta Paediatr. 2007;96:487–91.CrossRefPubMedGoogle Scholar
  16. 16.
    Scherpereel A, Gentina T, Grigoriu B, Sénéchal S, Janin A, Tsicopoulos A, et al. Overexpression of endocan induces tumor formation. Cancer Res. 2003;63:6084–9.PubMedGoogle Scholar
  17. 17.
    Huang GW, Tao YM, Ding X. Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci. 2009;54:389–94.CrossRefPubMedGoogle Scholar
  18. 18.
    Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono HA, et al. Clinicopathological properties of poorly-differentiated adenocarcinoma of the stomach: comparison of solid- and non-solid-types. Anticancer Res. 2006;26:639–46.PubMedGoogle Scholar
  19. 19.
    Zuo L, Zhang SM, Hu RL, Zhu HQ, Zhou Q, Gui SY, et al. Correlation between expression and differentiation of endocan in colorectal cancer. World J Gastroenterol. 2008;14:4562–8.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Wobbes T, Thomas CM, Segers MF, Nagengast FM. Evaluation of seven tumor markers (CA 50, CA 19–9, CA 19–9 TruQuant, CA 72–4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma. Cancer. 1992;69:2036–41.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Zhongchuan Lv
    • 1
  • Yongsheng Fan
    • 2
  • Hongbing Chen
    • 1
  • Dawei Zhao
    • 1
  1. 1.Department of Gastrointestinal SurgeryYantai Yuhuangding HospitalYantaiChina
  2. 2.Department of General SurgeryYantai Qixia People’s HospitalYantaiChina

Personalised recommendations